Press releases
- Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
- Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
- Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
- Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
- Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
- Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
- Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023
More ▼
Key statistics
As of last trade, Poseida Therapeutics Inc (2RZ:FRA) traded at 1.87, 27.74% above the 52 week low of 1.46 set on Aug 07, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.88 |
---|---|
High | 1.88 |
Low | 1.87 |
Bid | 1.94 |
Offer | 2.02 |
Previous close | 1.88 |
Average volume | 222.22 |
---|---|
Shares outstanding | 96.49m |
Free float | 63.18m |
P/E (TTM) | -- |
Market cap | 197.80m USD |
EPS (TTM) | -1.38 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 14:29 BST.
More ▼